EMERYVILLE, Calif., Aug. 5, 2011 /PRNewswire/ -- CORRECTED -- Bionovo, Inc. (NASDAQ: BNVI) today announced second quarter highlights and financial results for the three months ended June 30, 2011.
"We have made excellent progress on our menopausal hot flash drug candidate, MF101, or Menerba™, during the past quarter, delivering on milestones and commitments," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "We have completed the tasks which were required for us to begin the phase 3 clinical trial for Menerba, and we are on track to initiate the trial in the third quarter."
Key Events and Milestones
Second Quarter ResultsTotal operating expenses for the three months ending June 30, 2011 were $6.4 million compared to $4.1 million for the same period in 2010. Total operating expenses for the second quarter included costs associated with the start-up of our cGMP manufacturing facility in Hayward, California in preparation for the Phase 3 clinical trial of Menerba. The Company also launched the production of ten clinical batches of Menerba, completed 13-week animal toxicology studies evaluating the safety of Menerba and completed enrollment to a tolerability clinical trial assessing the safety and tolerability of higher doses of Menerba to be evaluated in the Company's Phase 3 trial of Menerba.
The Company reported a net loss for the three months ended June 30, 2011 of $7.9 million, or $0.14 per share, compared with a net loss of $4.1 million, or $0.19 per share, for the same period in 2010. The increase in net loss is primarily due to the increase in operating expenses as described above combined with the change in fair value of the Company's warrant liability of $1.4 million included in non-operating expense for the three months ended June 30, 2011.
The Company ended the quarter with $13.0 million in cash, cash equivalents and short term investments, and began the year with $2.6 million, a net increase of $10.4 million; the Company began the quarter with $23.1 million, a decrease of $10.1 million during the quarter. The cash balance at the end of the quarter reflects the proceeds of the Company's February 2011 public offering offset by operating expenses and capital expenditures to support the Menerba manufacturing facility in Hayward, California.
Conference CallBionovo will conduct a conference call and webcast to review the Company's financial results, in September, 2011, when further information on the non-clinical and clinical progress of Menerba will also be provided.
About Bionovo, Inc.Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.
Forward Looking StatementsThis release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Financial Tables on Following PagesBionovo, Inc.(A Development Stage Company)Condensed Consolidated Statements of Operations(Unaudited, in thousands, except per share data)Three months ended
June 30,Six months ended
from February 1,
2002 (Date of
,858Operating expenses:Research and development
5,5063,3289,3907,13563,738General and administrative
----1,964Total operating expenses
6,4374,11611,3158,77488,755Loss from operations
(6,437)(4,102)(11,250)(8,760)(86,897)Other income (expense):Change in fair value of warrant liability
(25)(10)(54)(24)(575)Other income (expense)
3(14)3(11)(202)Total other income (expense)
(83,128)Basic and diluted net loss per common share
$ (0.14)$ (0.19)$ (0.20)$ (0.41)$
(6.43)Shares used in computing basic and diluted
net loss per share
54,56121,52449,08621,51612,919Bionovo, Inc.(A Development Stage Company) Consolidated Balance Sheets(in thousands, except share data)June 30,
2010(unaudited)ASSETSCurrent assets:Cash and cash equivalents
933973Other current assets
502396Total current assets
14,4354,056Property and equipment, net
12,3266,647Patent pending, net
2,982LIABILITIES AND SHAREHOLDERS’ EQUITYCurrent liabilities:Accounts payable
55Accrued compensation and benefits
594901Current portion of lease obligations
1,0401,055Current portion of notes payable
10,3331,843Other current liabilities
1,309970Total current liabilities
13,6725,464Non-current portion of lease obligations
388836Non-current portion of notes payable
14,1376,381Commitments and contingenciesShareholders’ equity:Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding
--Common stock $0.0001 par value, 340,000,000 shares authorized, 54,561,312 and 24,530,112 shares outstanding at June 30, 2011 and December 31, 2010, respectively
52Additional paid-in capital
98,37480,145Accumulated other comprehensive income
(83,128)(73,546)Total shareholders’ equity
15,2546,601Total liabilities and shareholders’ equity
2,982* The balance sheet at December 31, 2010 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
|SOURCE Bionovo, Inc.|
Copyright©2010 PR Newswire.
All rights reserved